Bullish
Jay Woods, chief global strategist at Freedom Capital Markets, has highlighted Biogen Inc. (BIIB) as his top biotech pick, noting its multiple focuses...
Bullish
Jay Woods, chief global strategist at Freedom Capital Markets, has recommended investing in the biotech sector, specifically picking Biogen Inc. (BIIB...
Bearish
Shares of Biogen Inc (BIIB) recently rallied by 3.0% to $216.12, placing the stock 12.7% above its GF Value™ of $191.81, indicating it is "Modestly Ov...
Neutral
Biogen (NASDAQ: BIIB) has announced that it expects significant one-time R&D milestone charges to impact its earnings in the second and third quarters...
Biogen's stock rose 9.9% following its US$1 billion acquisition of RayThera Inc. and the FDA's Breakthrough Therapy designation for Salanersen. These ...
Biogen is shifting its growth strategy from its established multiple sclerosis and Spinraza products to four new drugs: Leqembi, Skyclarys, Qalsody, a...
Shares of Biogen (BIIB) surged 5.6% following several positive developments. These include the acquisition of RayThera Inc., an FDA Breakthrough Thera...
Bullish
Biogen (BIIB) shares jumped 5.6% after a series of positive growth signals, including the acquisition of RayThera Inc. for $1 billion, an FDA Breakthr...
Bullish
Biogen (BIIB) stock has reached a new 52-week high of $206.21, marking an impressive 61.26% increase over the last year, with its market capitalizatio...
Bearish
Biogen has expanded its patent infringement battle over the spinal muscular atrophy drug Spinraza, suing Cipla Ltd. for allegedly copying the treatmen...
Bullish
Biogen (NASDAQ: BIIB) announced its agreement to acquire private biotechnology company RayThera Inc. for up to $1 billion, intending to expand its imm...
Bullish
Biogen is acquiring San Diego-based biotech RayThera for up to $1 billion to expand its early-stage immunology pipeline. The Cambridge drugmaker's dea...
Biogen has announced the acquisition of RayThera in a deal potentially valued at up to $1 billion. This strategic move aims to expand Biogen's portfol...
Biogen has agreed to acquire private immunology biotech RayThera Inc. for up to $1 billion, significantly expanding its pipeline with a new class of u...
Bullish
Biogen Inc. has announced its agreement to acquire RayThera Inc., a private biotechnology company specializing in small molecule therapies for immunol...
Neutral
The Multiple Sclerosis (MS) market is anticipated to reach USD 30,597 million by 2034, growing at a CAGR of 3.8% across key markets, driven by increas...
Biogen Canada expressed disappointment after negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYCLARYS™ (omaveloxolone), a treat...
Bullish
City Therapeutics, a Cambridge-based biotechnology company, launched in October 2024 with $135 million to develop next-generation RNA interference med...
Bullish
Shares of Biogen (BIIB) have outperformed the iShares Biotechnology ETF (IBB) over the past three months, year-to-date, and 52 weeks. The company, a l...
Neutral
Representative Maria Elvira Salazar of Florida recently purchased Biogen (NASDAQ: BIIB) stock worth between $115,010 and $375,000, with the transactio...